Direct-Acting Oral Anticoagulants in Heparin-Induced Thrombocytopenia

April 12, 2021
Heparin-induced thrombocytopenia is uncommon, but life-threatening. Current parenteral therapy, including FDA approved argatroban and off-label bivalirudin and fondaparinux, is costly and argatroban is associated with frequent monitoring. Bridging to warfarin oral therapy also requires the use of parenteral therapy and subsequent INR monitoring once bridged. This practice may be costly, extend the patient’s hospital stay, and interfere with quality of life by adding cumbersome monitoring requirements. Robust data focusing on direct-acting oral anticoagulants as alternative oral treatment for HIT is currently lacking. This CE presentation will present what data is available to assist pharmacy staff to make informed decisions and recommendations regarding HIT therapy that would benefit individual patients.

Target Audience

  • Pharmacists
  • Pharmacy technicians

Learning Objectives

Pharmacist learning objectives

  1. Describe the epidemiology, pathophysiology and clinical features of heparin-induced thrombocytopenia (HIT)
  2. Compare guideline recommendations for the treatment of HIT from the American College of Chest Physicians and the American Society of Hematology
  3. Summarize the current gold standard for treatment of HIT including mechanism of action, dosing and monitoring parameters for agents
  4. Identify commonly used anticoagulants
  5. Review FDA approved indications, mechanism of action and safety profile of direct-acting oral anticoagulants (DOACs)
  6. Evaluate primary literature for the efficacy and safety of using DOACs in HIT

Pharmacy technician learning objectives

  1. Identify commonly used anticoagulants

Additional Information

AttachmentSize
PDF icon Helpful Tips for Users.pdf157.72 KB
File Information for CE Credit - Direct-Acting Oral Anticoagulants - Apr 12 2021.docx125.48 KB
Course summary
Available credit: 
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CE – Attendance
Course opens: 
04/12/2021
Course expires: 
05/26/2021
Event starts: 
04/12/2021 - 12:00pm CDT
Event ends: 
04/12/2021 - 1:00pm CDT
Add to calendar: 
ChristianaCare
Newark, DE
United States
Relevant financial relationships: Planning committee members and presenters have nothing to disclose
The presenter will discuss off-label use of drugs
 
Planning committee members
Kaitlyn Harper, PharmD
Clinical Pharmacist
ChristianaCare
 
Anastasiya Malanchuk, PharmD
PGY-1 Pharmacy Resident
ChristianaCare
 
Course reviewer
Katrina K. Harper, PharmD, MBA, BCPS, BCSCP
Clinical Pharmacy Director, Sourcing Operations
Center for Pharmacy Practice Excellence
Vizient, Inc.
 
Presenter
Anastasiya Malanchuk, PharmD
PGY-1 Pharmacy Resident
ChristianaCare
Joint Accreditation Statement:
 
In support of improving patient care, this activity has been planned and implemented by Vizient, Inc. and ChristianaCare.  Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
____________________________________________
 
Designation Statements:
 
PHARMACY
Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.
Universal Activity Number: JA0006103-9999-21-081-L01-P
Universal Activity Number: JA0006103-9999-21-081-L01-T
CEU
Vizient, Inc. will award CEUs to each participant who successfully completes this program. The CEU is a nationally recognized unit of measure for continuing education and training programs that meet certain criteria (1 contact hour = 0.1 CEU).

Available Credit

  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CE – Attendance
Please login or register to take this course.